Foghorn Therapeutics pauses enrollment in cancer study

(Reuters) – Foghorn Therapeutics Inc said on Monday it has paused enrollment in an early-stage study of the company’s experimental cancer drug due to safety concerns.

(Reporting by Khushi Mandowara in Bengaluru; Editing by Devika Syamnath)